Cancer Treatment-Induced Accelerated Aging in Cancer Survivors: Biology and Assessment

doi:10.3390/cancers13030427

Review

. 2021 Jan 23;13(3):427.

doi: 10.3390/cancers13030427.

Cancer Treatment-Induced Accelerated Aging in Cancer Survivors: Biology and Assessment

Shuo Wang¹, Anna Prizment^{2

3}, Bharat Thyagarajan^{3

4}, Anne Blaes^{2

3}

Affiliations

¹ Division of Epidemiology and Community Health, School of Public Health, University of Minnesota, Minneapolis, MN 55455, USA.
² Division of Hematology, Oncology and Transplantation, Medical School, University of Minnesota, Minneapolis, MN 55455, USA.
³ Masonic Cancer Center, University of Minnesota, Minneapolis, MN 55455, USA.
⁴ Department of Laboratory Medicine and Pathology, Medical School, University of Minnesota, Minneapolis, MN 55455, USA.

PMID: 33498754
PMCID: PMC7865902
DOI: 10.3390/cancers13030427

Review

Cancer Treatment-Induced Accelerated Aging in Cancer Survivors: Biology and Assessment

Shuo Wang et al. Cancers (Basel). 2021.

. 2021 Jan 23;13(3):427.

doi: 10.3390/cancers13030427.

Authors

Shuo Wang¹, Anna Prizment^{2

3}, Bharat Thyagarajan^{3

4}, Anne Blaes^{2

3}

Affiliations

¹ Division of Epidemiology and Community Health, School of Public Health, University of Minnesota, Minneapolis, MN 55455, USA.
² Division of Hematology, Oncology and Transplantation, Medical School, University of Minnesota, Minneapolis, MN 55455, USA.
³ Masonic Cancer Center, University of Minnesota, Minneapolis, MN 55455, USA.
⁴ Department of Laboratory Medicine and Pathology, Medical School, University of Minnesota, Minneapolis, MN 55455, USA.

PMID: 33498754
PMCID: PMC7865902
DOI: 10.3390/cancers13030427

Abstract

Rapid improvements in cancer survival led to the realization that many modalities used to treat or control cancer may cause accelerated aging in cancer survivors. Clinically, "accelerated aging" phenotypes in cancer survivors include secondary cancers, frailty, chronic organ dysfunction, and cognitive impairment, all of which can impact long-term health and quality of life in cancer survivors. The treatment-induced accelerated aging in cancer survivors could be explained by telomere attrition, cellular senescence, stem cell exhaustion, DNA damage, and epigenetic alterations. Several aging clocks and biomarkers of aging have been proposed to be potentially useful in estimating biological age, which can provide specific information about how old an individual is biologically independent of chronological age. Measuring biological age in cancer survivors may be important for two reasons. First, it can better predict the risk of cancer treatment-related comorbidities than chronological age. Second, biological age may provide additional value in evaluating the effects of treatments and personalizing cancer therapies to maximize efficacy of treatment. A deeper understanding of treatment-induced accelerated aging in individuals with cancer may lead to novel strategies that reduce the accelerated aging and improve the quality of life in cancer survivors.

Keywords: accelerated aging; cancer treatment; cellular senescence.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

**Figure 1**
Hypothesized accelerated aging due to cancer treatments, adapted with permission from Guida et al. (2019) [9].

**Figure 2**
Possible biological mechanisms and potential measurements of treatment-induced accelerating aging in cancer survivors.

See this image and copyright information in PMC

Cited by

Physical Activity and Epigenetic Aging in Breast Cancer Treatment.
Moulton C, Grazioli E, Ibáñez-Cabellos JS, Murri A, Cerulli C, Silvestri M, Caporossi D, Pallardó FV, García-Giménez JL, Magno S, Rossi C, Duranti G, Mena-Molla S, Parisi A, Dimauro I. Moulton C, et al. Int J Mol Sci. 2024 Aug 6;25(16):8596. doi: 10.3390/ijms25168596. Int J Mol Sci. 2024. PMID: 39201283 Free PMC article.
Women at heart: Introducing gender cardio-oncology.
Canale ML, Bisceglia I, Gallucci G, Russo G, Camerini A, Di Fusco SA, Paccone A, Camilli M, Fiscella D, Lestuzzi C, Turazza FM, Gulizia MM, Pavan D, Maurea N, Gabrielli D, Oliva F, Colivicchi F. Canale ML, et al. Front Cardiovasc Med. 2022 Nov 23;9:974123. doi: 10.3389/fcvm.2022.974123. eCollection 2022. Front Cardiovasc Med. 2022. PMID: 36505385 Free PMC article. Review.
Immunosenescence in Childhood Cancer Survivors and in Elderly: A Comparison and Implication for Risk Stratification.
Lázničková P, Bendíčková K, Kepák T, Frič J. Lázničková P, et al. Front Aging. 2021 Jul 19;2:708788. doi: 10.3389/fragi.2021.708788. eCollection 2021. Front Aging. 2021. PMID: 35822014 Free PMC article. Review.
Accelerated Aging in Cancer Survivors: Cellular Senescence, Frailty, and Possible Opportunities for Interventions.
Wang S, El Jurdi N, Thyagarajan B, Prizment A, Blaes AH. Wang S, et al. Int J Mol Sci. 2024 Mar 14;25(6):3319. doi: 10.3390/ijms25063319. Int J Mol Sci. 2024. PMID: 38542292 Free PMC article. Review.
Impact of Short-Term Creatine Supplementation on Muscular Performance among Breast Cancer Survivors.
Parsowith EJ, Stock MS, Kocuba O, Schumpp A, Jackson K, Brooks AM, Larson A, Dixon M, Fairman CM. Parsowith EJ, et al. Nutrients. 2024 Mar 27;16(7):979. doi: 10.3390/nu16070979. Nutrients. 2024. PMID: 38613014 Free PMC article. Clinical Trial.

See all "Cited by" articles

References

1. Sebastiani P., Thyagarajan B., Sun F., Schupf N., Newman A.B., Montano M., Perls T.T. Biomarker signatures of aging. Aging Cell. 2017;16:329–338. doi: 10.1111/acel.12557. - DOI - PMC - PubMed
1. Soto-Perez-De-Celis E., Li D., Yuan Y., Lau Y.M., Hurria A. Functional versus chronological age: Geriatric assessments to guide decision making in older patients with cancer. Lancet Oncol. 2018;19:e305–e316. doi: 10.1016/S1470-2045(18)30348-6. - DOI - PubMed
1. Olsen J.H., Möller T., Anderson H., Langmark F., Sankila R., Tryggvadóttír L., Winther J.F., Rechnitzer C., Jonmundsson G., Christensen J., et al. Lifelong Cancer Incidence in 47 697 Patients Treated for Childhood Cancer in the Nordic Countries. J. Natl. Cancer Inst. 2009;101:806–813. doi: 10.1093/jnci/djp104. - DOI - PubMed
1. Reulen R.C., Frobisher C., Winter D.L., Kelly J., Lancashire E.R., Stiller C.A., Pritchard-Jones K., Jenkinson H.C., Hawkins M.M., British Childhood Cancer Survivor Study Steering Group Long-term Risks of Subsequent Primary Neoplasms Among Survivors of Childhood Cancer. JAMA. 2011;305:2311–2319. doi: 10.1001/jama.2011.747. - DOI - PubMed
1. Mohty B., Mohty M. Long-term complications and side effects after allogeneic hematopoietic stem cell transplantation: An update. Blood Cancer J. 2011;1:e16. doi: 10.1038/bcj.2011.14. - DOI - PMC - PubMed

Publication types

Actions

LinkOut - more resources

Full Text Sources
Other Literature Sources
- scite Smart Citations

[1] Sebastiani P., Thyagarajan B., Sun F., Schupf N., Newman A.B., Montano M., Perls T.T. Biomarker signatures of aging. Aging Cell. 2017;16:329–338. doi: 10.1111/acel.12557. - DOI - PMC - PubMed

[2] Sebastiani P., Thyagarajan B., Sun F., Schupf N., Newman A.B., Montano M., Perls T.T. Biomarker signatures of aging. Aging Cell. 2017;16:329–338. doi: 10.1111/acel.12557. - DOI - PMC - PubMed

[3] Soto-Perez-De-Celis E., Li D., Yuan Y., Lau Y.M., Hurria A. Functional versus chronological age: Geriatric assessments to guide decision making in older patients with cancer. Lancet Oncol. 2018;19:e305–e316. doi: 10.1016/S1470-2045(18)30348-6. - DOI - PubMed

[4] Soto-Perez-De-Celis E., Li D., Yuan Y., Lau Y.M., Hurria A. Functional versus chronological age: Geriatric assessments to guide decision making in older patients with cancer. Lancet Oncol. 2018;19:e305–e316. doi: 10.1016/S1470-2045(18)30348-6. - DOI - PubMed

[5] Olsen J.H., Möller T., Anderson H., Langmark F., Sankila R., Tryggvadóttír L., Winther J.F., Rechnitzer C., Jonmundsson G., Christensen J., et al. Lifelong Cancer Incidence in 47 697 Patients Treated for Childhood Cancer in the Nordic Countries. J. Natl. Cancer Inst. 2009;101:806–813. doi: 10.1093/jnci/djp104. - DOI - PubMed

[6] Olsen J.H., Möller T., Anderson H., Langmark F., Sankila R., Tryggvadóttír L., Winther J.F., Rechnitzer C., Jonmundsson G., Christensen J., et al. Lifelong Cancer Incidence in 47 697 Patients Treated for Childhood Cancer in the Nordic Countries. J. Natl. Cancer Inst. 2009;101:806–813. doi: 10.1093/jnci/djp104. - DOI - PubMed

[7] Reulen R.C., Frobisher C., Winter D.L., Kelly J., Lancashire E.R., Stiller C.A., Pritchard-Jones K., Jenkinson H.C., Hawkins M.M., British Childhood Cancer Survivor Study Steering Group Long-term Risks of Subsequent Primary Neoplasms Among Survivors of Childhood Cancer. JAMA. 2011;305:2311–2319. doi: 10.1001/jama.2011.747. - DOI - PubMed

[8] Reulen R.C., Frobisher C., Winter D.L., Kelly J., Lancashire E.R., Stiller C.A., Pritchard-Jones K., Jenkinson H.C., Hawkins M.M., British Childhood Cancer Survivor Study Steering Group Long-term Risks of Subsequent Primary Neoplasms Among Survivors of Childhood Cancer. JAMA. 2011;305:2311–2319. doi: 10.1001/jama.2011.747. - DOI - PubMed

[9] Mohty B., Mohty M. Long-term complications and side effects after allogeneic hematopoietic stem cell transplantation: An update. Blood Cancer J. 2011;1:e16. doi: 10.1038/bcj.2011.14. - DOI - PMC - PubMed

[10] Mohty B., Mohty M. Long-term complications and side effects after allogeneic hematopoietic stem cell transplantation: An update. Blood Cancer J. 2011;1:e16. doi: 10.1038/bcj.2011.14. - DOI - PMC - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Cancer Treatment-Induced Accelerated Aging in Cancer Survivors: Biology and Assessment

Affiliations

Cancer Treatment-Induced Accelerated Aging in Cancer Survivors: Biology and Assessment

Authors

Affiliations

Abstract

Conflict of interest statement

Figures

Similar articles

Cited by

References

Publication types

LinkOut - more resources

Full Text Sources

Other Literature Sources